Sedation, an unpleasant, undesirable and potentially dangerous side-effect of many psychotropic drugs

Human Psychopharmacology

Volumn 19, Issue 2, 2004, Pages 135-139

  Bourin, Michel ^a   Briley, Mike ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b NeuroBiz Consulting and Communication   (France)

Author keywords

Antidepressants; Anxiolytics; Neuroleptics; Sedation; Somnolence

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALIMEMAZINE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CLORAZEPATE; DESIPRAMINE; DIPHENHYDRAMINE; FEXOFANIDINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PRAZEPAM; PROMETHAZINE; PSYCHOTROPIC AGENT; REBOXETINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY; ANXIETY DISORDER; ARTICLE; CHANNEL GATING; COGNITION; CRITICAL FLICKER FUSION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; HUMAN; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; RESPONSE TIME; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDE; VISUAL ANALOG SCALE;

ANIMALS; HUMANS; PSYCHOTROPIC DRUGS; REACTION TIME; SLEEP;

EID: 1542726031     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.561     Document Type: Article

References (33)

1. Anttila SAK, Leinonen EVJ. 2001. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7: 249-264.
2. Bernstein DI, Schoenwette WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. 1997. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 79: 443-448.
3. Boissier JR, Simon P. 1965. Action de la caféine sur la mobilité spontanée de la souris. Arch Int Pharmacodyn 158: 212-221.
4. Bourin M. 1989. Les Benzodiazépines. Editions Ellipses: Paris.
5. Bourin M, Baker GB. 1996. The future of antidepressants. Biomed Pharmacother 50: 7-12.
6. Bourin M, Hascoët M, Mansouri B, Bradwejn J. 1992. Comparison of behavioural effects after single and repeated administration of four benzodiazepines in three mice behavioural models. J Psychiatry Neurosci 17: 72-77.
7. Bourin M, Le Martret JB. 1985. La prescription sédative en odontologie. Chirurgien-Dentiste 291: 49-51.
8. Bourin M, Nic Dhonnchadha BA. 2001. Psychopharmacology of hypnotics. Klinik Psikofarmakologi Bülteni 11: 124-131.
9. Buckley PF. 1999. The role of typical and atypical antipsychotic medication in the management of agitation and aggression. J Clin Psychiatry 60: 52-60.
10. Curry SH, Marshall JHL, Davis JM, Janowsky DS. 1978. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry Scand 58: 149-173.
11. De Vane CL. 1995. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 10: S185-S193.
12. Delay J, Deniker P. 1961. In Méthodes Chimiothérapeutiques en Psychiatrie. Masson: Paris.
13. Faraone SV, Biederman J. 1999. The neurobiology of attention deficit hyperactivity disorder. In Neurobiology of Mental Illness, Charney DS, Nestler EJ, Bunney BS (eds). Oxford University Press: New York, 788-801.
14. Hascoët M, Bourin M, Bradwejn J. 1991. Behavioural models in mice: implication of the α one adrenergic system. Progr Neuropsychopharmacol Biol Psychiatry 15: 825-840.
15. Hindmarch I. 1997. The effects of antidepressants on psychomotor function with particular reference to reboxetine. Eur Neuropsychopharmacol 7: S17-S21.
16. Hindmarch I, Rigney U, Stanley N, Briley M. 2000. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 49: 118-125.
17. Hindmarch I, Shamsi Z. 1999. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 29: 133-142.
18. Jolliet P, Bourin M. 1998. Pharmacology of new antipsychotic drugs: are they stabilizers of schizophrenic psychosis? Drug News Perspect 11: 625-630.
19. Kapsambelis V, Gekiere CL, Ginestet D. 1990. Classifications cliniques de neuroleptiques. Etude clinique et perspectives actuelles. Encéphale 16: 63-70.
20. Lane RM, O'Hanlon JF. 1999. Cognitive and psychomotor effects of antidepressants with emphasis on selective serotonin reuptake inhibitors and the depressed elderly patient. German J Psychiatry 2: 1-28.
21. Majeroni BA. 1998. The pharmacologic treatment of depression. J Am Board Fam Pract 11: 127-139.
22. Mathers DA, Barler JL. 1980. (-) Pentobarbital opens ion channels of long duration in cultured mouse spinal neurons. Science 209: 507-509.
23. Michelson D, Allen AJ, Busner J, et al. 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108: E83.
24. Norris H. 1971. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.
25. Puech AJ, Lacomblez L. 1990. Les Neuroleptiques. In Les Médicaments en Neurologie et Psychiatrie, Bourin M (ed.). Masson: Paris; 26-52.
26. Richelson E, Nelson A. 1984. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103: 197-204.
27. Simon P, Chermat R, Doare L, Bourin M, Farinotti R. 1982. Interactions imprévues de divers psychotropes avec les effets du barbital et du pentobarbital chez la souris. J Pharmacol 13: 241-252.
28. Simon P, Lecrubier Y, Puech AJ. 1984. Classification des neuroleptiques. Rev Praticien 34: 589-594.
29. Spencer T, Biederman J, Wilens T, et al. 1998. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155: 693-695.
30. Study RE, Barker JL. 1981. Diazepam and (-)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma aminobutyric acid responses in cultured central neurons. Proc Nat Acad Sci USA 78: 7180-7184.
31. Wode-Helgodt B, Fyro B, Sedvall G. 1978. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with doses of chlorpromazine. Acta Psychiatr Scand 58: 149-173.
32. Wolf MA, Villeneuve A. 1990. Les effets indésirables des neuroleptiques. Encéphale 16: 111-124.
33. Zametkin AJ, Rapoport JL. 1987. Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review. In Psychopharmacology: The Third Generation of Progress, Meltzer HY (ed.). Raven Press: New York; 837-842.